tiprankstipranks
Trending News
More News >
Scandion Oncology A/S (DE:8VY)
FRANKFURT:8VY

Scandion Oncology A/S (8VY) Price & Analysis

Compare
0 Followers

8VY Stock Chart & Stats


Financials

8VY FAQ

What was Scandion Oncology A/S’s price range in the past 12 months?
Scandion Oncology A/S lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
    What is Scandion Oncology A/S’s market cap?
    Scandion Oncology A/S’s market cap is €372.85K.
      When is Scandion Oncology A/S’s upcoming earnings report date?
      Scandion Oncology A/S’s upcoming earnings report date is May 22, 2025 which is 16 days ago.
        How were Scandion Oncology A/S’s earnings last quarter?
        Scandion Oncology A/S released its earnings results on Mar 12, 2025. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.
          Is Scandion Oncology A/S overvalued?
          According to Wall Street analysts Scandion Oncology A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Scandion Oncology A/S pay dividends?
            Scandion Oncology A/S does not currently pay dividends.
            What is Scandion Oncology A/S’s EPS estimate?
            Scandion Oncology A/S’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Scandion Oncology A/S have?
            Scandion Oncology A/S has 234,761,410 shares outstanding.
              What happened to Scandion Oncology A/S’s price movement after its last earnings report?
              Scandion Oncology A/S reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Scandion Oncology A/S?
                Currently, no hedge funds are holding shares in DE:8VY

                Company Description

                Scandion Oncology A/S

                Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
                Similar Stocks
                Company
                Price & Change
                Follow
                LIDDS AB
                Xintela AB
                Lipigon Pharmaceuticals AB
                CombiGene AB
                Sprint Bioscience AB
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis